ecent evidence demonstrates that exercise induces delayed cardioprotection similar to that of ischemic preconditioning (PC), ia mechanisms that are presently unknown. Unlike ischemic or pharmacologic PC, exercise PC is triggered by a physiologic itimulus and thus would appear to be a natural means for achieving cardioprotection. The overall objective of this proposal is .0 elucidate the molecular mechanisms .underlying the newly-discovered phenomenon of exercise PC. Our fundamental lypothesis is that exercise-induced release of NO (via eNOS) activates a signal transduction cascade that includes PKCe, Src/Lck, and multiple transcription factors and culminates in the upregulation of iNOS, which then mediates the protection, either singularly or in conjunction with eNOS. A broad multidisciplinary approach will be used that will combine diverse echniques (integrative physiology, protein chemistry, mass spectrometry, biochemistry, cell biology, molecular biology, gene .argeting, and transgenesis) and will integrate genetic information at the molecular level with biochemical information at the jrotein structure level and physiological information at the whole animal level. Unequivocal evidence for or against an Dbligatory role of three specific kinases (PKCe, Src,.Lck) in exercise PC will be provided by the use of a novel dominant negative PKCe transgenic mouse line and Src and Lck knockout mice, this will enable us to achieve, for the first time, (inase-specific modulation of PKCe. Src.and Lck during exercise. The role of PKCs in initiating exercise PC will be onclusivelv established by determining the effects of specific transgenic inhibition of this isozyme. The kinase-specific activity of all seven Src PTKs expressed in the mouse heart (Fyn, Fgr, Yes, Src, Lyn, Lck, and Blk) will be directly measured at serial times after exercise PC. The role of Src PTKs in triggering versus mediating exercise PC'will be discerned by comparing inhibition of these kinases on days 1 and 2 (during the exercise stimulus) versus day 3 (during coronary occlusion). Targeted disruption of the Src and Lck gene will be employed to conclusively establish the specific function of individual PTKs in the PC protection. The transcription factors responsible for exercise PC will be systematically interrogated by using mice with targeted genetic ablation of each of the main factors known to bind to the iNOS gene (IRF-1, TNF-a, STAT1, CREB, AP-1, IL-2, and IL-6). The specific NOS isoforms responsible for initiating as well as mediating exercise PC will be conclusively identified by targeted gene disruption of eNOS, iNOS, and nNOS. The post-translational modulation of iNOS 24 h after exercise will be elucidated by identifying the precise phosphorylation site(s) on iNOS with HPLC coupled- electrospray ionization mass spectrometry. Finally, the role of Src PTKs in the post-translational modulation of iNOS will be established by measuring iNOS activity and tyrosine phosphorylation in the absence and presence of Src PTK inhibitors. This proposal should produce important new insights into the molecular mechanisms whereby the heart adapts not only to physical stress but also to stress in general. Elucidation of the mechanism of exercise PC may have important therapeutic implications.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HL055757-13
Application #
7269782
Study Section
Special Emphasis Panel (NSS)
Program Officer
Liang, Isabella Y
Project Start
1995-05-01
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
13
Fiscal Year
2007
Total Cost
$535,392
Indirect Cost
Name
University of Louisville
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
057588857
City
Louisville
State
KY
Country
United States
Zip Code
40292
Tang, Xian-Liang; Li, Qianhong; Rokosh, Gregg et al. (2016) Long-Term Outcome of Administration of c-kit(POS) Cardiac Progenitor Cells After Acute Myocardial Infarction: Transplanted Cells Do not Become Cardiomyocytes, but Structural and Functional Improvement and Proliferation of Endogenous Cells Persist for at L Circ Res 118:1091-105
Muthusamy, Senthilkumar; DeMartino, Angelica M; Watson, Lewis J et al. (2014) MicroRNA-539 is up-regulated in failing heart, and suppresses O-GlcNAcase expression. J Biol Chem 289:29665-76
Bolli, Roberto; Tang, Xian-Liang; Sanganalmath, Santosh K et al. (2013) Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 128:122-31
Zafir, Ayesha; Readnower, Ryan; Long, Bethany W et al. (2013) Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells. Stem Cells 31:765-75
Sanganalmath, Santosh K; Bolli, Roberto (2013) Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 113:810-34
Stein, Adam B; Bolli, Roberto; Dawn, Buddhadeb et al. (2012) Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. J Mol Cell Cardiol 52:228-36
Tang, Xian-Liang; Sanganalmath, Santosh K; Sato, Hiroshi et al. (2011) Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction. PLoS One 6:e25320
Zuba-Surma, Ewa K; Guo, Yiru; Taher, Hisham et al. (2011) Transplantation of expanded bone marrow-derived very small embryonic-like stem cells (VSEL-SCs) improves left ventricular function and remodelling after myocardial infarction. J Cell Mol Med 15:1319-28
Lefer, David J; Bolli, Roberto (2011) Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation. J Cardiovasc Pharmacol Ther 16:332-9
Li, Qianhong; Guo, Yiru; Ou, Qinghui et al. (2011) Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences. Basic Res Cardiol 106:1367-77

Showing the most recent 10 out of 125 publications